Skip to main content

Table 3 Overall rankings by anatomic location of uveitis and corresponding worth estimatesa

From: Corticosteroid-sparing therapy: practice patterns among uveitis specialists

Rank Anterior Intermediate Posterior/pan
Used Preferred Used Preferred Used Preferred
1 MTX (0.60) MTX (0.30) MTX (0.24) MMF (0.23) MMF (0.21) MMF (0.22)
2 MMF (0.13) MMF (0.22) MMF (0.21) MTX (0.20) MTX (0.19) MTX (0.18)
3 INF (0.07) INF (0.14) AZA (0.13) INF (0.16) AZA (0.14) INF (0.15)
4 AZA (0.07) ADA (0.13) CSA (0.13) ADA (0.13) CSA (0.14) ADA (0.15)
5 ADA (0.06) AZA (0.10) INF (0.13) AZA (0.12) INF (0.13) CSA (0.12)
6 CSA (0.05) CSA (0.07) ADA (0.11) CSA (0.11) ADA (0.11) AZA (0.11)
7 CTX (0.02) CTX (0.04) CTX (0.05) CTX (0.05) CTX (0.08) CTX (0.07)
  1. MTX methotrexate, MMF mycophenolate mofetil, AZA azathioprine, CSA cyclosporine, CTX cyclophosphamide, INF infliximab, ADA adalimumab
  2. aCalculated using a Bradley–Terry model: represent what fraction of overall worth could be assigned to each treatment and are used to estimate an overall ranking (e.g., based on the collective rankings of the respondents, methotrexate could be assigned 60% of the collective preference as the most used initial treatment for anterior uveitis)